Does Rallies show 13F holders for APVO?

Yes. Rallies tracks hedge fund and 13F ownership data for APVO, including fund names, share counts, latest tracked quarter, and position changes when available.

Is APVO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for APVO. It does not provide personalized investment advice.

APVO (Aptevo Therapeutics Inc) Stock Analysis - Hedge Fund Holdings

Aptevo Therapeutics Inc (APVO) is a publicly traded Healthcare sector company. As of May 21, 2026, APVO trades at $4.57 with a market cap of $5.47M and a P/E ratio of -0.05. APVO moved +0.00% today. Year to date, APVO is -45.25%; over the trailing twelve months it is -95.92%. Its 52-week range spans $3.80 to $6,859.80. Analyst consensus is buy with an average price target of $21.00. Rallies surfaces APVO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns APVO stock?

Hedge funds tracked by Rallies that own APVO include Citadel Advisors, Renaissance Technologies, and Two Sigma. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Aptevo Therapeutics Inc.

APVO Key Metrics

Key financial metrics for APVO
Metric	Value
Price	$4.57
Market Cap	$5.47M
P/E Ratio	-0.05
EPS	$-87.27
Dividend Yield	0.00%
52-Week High	$6,859.80
52-Week Low	$3.80
Volume	433
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-25.97M
Gross Margin	0.00%

Top Hedge Funds Holding APVO

Citadel Advisors holds 111.63K shares of APVO, changed -57.41% as of Sep 30, 2024.
Renaissance Technologies holds 36.58K shares of APVO, changed -92.92% as of Sep 30, 2024.
Two Sigma holds 28.02K shares of APVO, changed +149.11% as of Sep 30, 2024.

Latest APVO News

Aptevo reports 87% clinical benefit in frontline AML trial; $60M credit line extends runway — May 13, 2026
Aptevo Posts 87% Clinical Benefit and 81% Remission in Frontline AML Trial — May 6, 2026
Aptevo’s AML Therapy Shows 86% Benefit, Secures $60 Million Equity Line — Mar 26, 2026
Mipletamig Combo Delivers 86% Benefit Rate, Zero CRS in 28 AML Patients — Mar 10, 2026

Recent APVO Insider Trades

Grant Grady III bought 13.51K (~$20.13K) on Nov 10, 2025.

APVO Analyst Consensus

1 analysts cover APVO: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $21.00.

Common questions about APVO

Who owns APVO stock?: Hedge funds tracked by Rallies that own APVO include Citadel Advisors, Renaissance Technologies, and Two Sigma. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Aptevo Therapeutics Inc.
Does Rallies show 13F holders for APVO?: Yes. Rallies tracks hedge fund and 13F ownership data for APVO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is APVO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for APVO. It does not provide personalized investment advice.